{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T00:05:37Z","timestamp":1793664337609,"version":"4.5.1"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":457,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2014,6]]},"abstract":"<jats:sec>\n            <jats:title\/>\n            <jats:p>Fatal hepatitis B virus (HBV) reactivation in lymphoma patients with \u201cresolved\u201d HBV infection (hepatitis B surface antigen [HBsAg] negative and hepatitis B core antibody [anti-HBc] positive) can occur, but the true incidence and severity remain unclear. From June 2009 to December 2011, 150 newly diagnosed lymphoma patients with resolved HBV infection who were to receive rituximab-CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone)-based chemotherapy were prospectively followed. HBV DNA was checked at baseline, at the start of each cycle of chemotherapy, and every 4 weeks for 1 year after completion of rituximab-CHOP chemotherapy. Patients with documented HBV reactivation were treated with entecavir at a dosage of 0.5 mg\/day for 48 weeks. HBV reactivation was defined as a greater than 10-fold increase in HBV DNA, compared with previous nadir levels, and hepatitis flare was defined as a greater than 3-fold increase in alanine aminotransferase (ALT) that exceeded 100 IU\/L. Incidence of HBV reactivation and HBV-related hepatitis flares was 10.4 and 6.4 per 100 person-year, respectively. Severe HBV-related hepatitis (ALT &gt;10-fold of upper limit of normal) occurred in 4 patients, despite entecavir treatment. Patients with hepatitis flare exhibited significantly higher incidence of reappearance of HBsAg after HBV reactivation (100% vs. 28.5%; <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.003). <jats:italic toggle=\"yes\">Conclusion<\/jats:italic>: In lymphoma patients with resolved HBV infections, chemotherapy-induced HBV reactivation is not uncommon, but can be managed with regular monitoring of HBV DNA and prompt antiviral therapy. Serological breakthrough (i.e., reappearance of HBsAg) is the most important predictor of HBV-related hepatitis flare. (Hepatology 2014;59:2092\u20132100)<\/jats:p>\n          <\/jats:sec>","DOI":"10.1002\/hep.26718","type":"journal-article","created":{"date-parts":[[2013,9,3]],"date-time":"2013-09-03T13:22:38Z","timestamp":1378214558000},"page":"2092-2100","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":242,"title":["Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: A prospective study"],"prefix":"10.1097","volume":"59","author":[{"given":"Chiun","family":"Hsu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsiao-Hui","family":"Tsou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shyh-Jer","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Chung","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Li","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woei-Yau","family":"Kao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Fang","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-Fung","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johnson","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Shyong","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hwei-Fang","family":"Tien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsang-Wu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Jer","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann-Lii","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-10-20251014","doi-asserted-by":"crossref","first-page":"844853","DOI":"10.1002\/hep.22106","article-title":"A revisit for prophylactic lamivudine for chemotherapyassociated hepatitis B reactivation in nonHodgkins lymphoma: a randomized trial.","volume":"47","author":"Hsu","year":"2008","journal-title":"Hepatology"},{"key":"R2-10-20251014","doi-asserted-by":"crossref","first-page":"17421749","DOI":"10.1053\/j.gastro.2003.09.026","article-title":"Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy.","volume":"125","author":"Lau","year":"2003","journal-title":"Gastroenterology"},{"key":"R3-10-20251014","first-page":"507539","article-title":"Chronic hepatitis B.","volume":"45","author":"Lok","year":"2007","journal-title":"Hepatology"},{"key":"R5-10-20251014","doi-asserted-by":"crossref","first-page":"209230","DOI":"10.1002\/hep.21051","article-title":"Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy.","volume":"43","author":"Yeo","year":"2006","journal-title":"Hepatology"},{"key":"R6-10-20251014","doi-asserted-by":"crossref","first-page":"431433","DOI":"10.1080\/10428190601059704","article-title":"Fulminant B hepatitis in a surface antigen and hepatitis B DNAnegative patient with diffuse large Bcell lymphoma after CHOP chemotherapy plus rituximab.","volume":"48","author":"Yamagata","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"R7-10-20251014","doi-asserted-by":"crossref","first-page":"10531056","DOI":"10.1111\/j.1365-2133.2006.07451.x","article-title":"Late lethal hepatitis B virus reactivation after rituximab treatment of lowgrade cutaneous Bcell lymphoma.","volume":"155","author":"Perceau","year":"2006","journal-title":"Br J Dermatol"},{"key":"R8-10-20251014","doi-asserted-by":"crossref","first-page":"5968","DOI":"10.1053\/j.gastro.2006.04.015","article-title":"Kinetic and risk of de novo hepatitis B infection in HBsAgnegative patients undergoing cytotoxic chemotherapy.","volume":"131","author":"Hui","year":"2006","journal-title":"Gastroenterology"},{"key":"R9-10-20251014","doi-asserted-by":"crossref","first-page":"605611","DOI":"10.1200\/JCO.2008.18.0182","article-title":"Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab.","volume":"27","author":"Yeo","year":"2009","journal-title":"J Clin Oncol"},{"key":"R10-10-20251014","doi-asserted-by":"crossref","first-page":"243250","DOI":"10.1111\/j.1600-0609.2010.01474.x","article-title":"Low incidence of hepatitis B virus reactivation during chemotherapy among diffuse large Bcell lymphoma patients who are HBsAgnegativeHBcAbpositive: a multicenter retrospective study.","volume":"85","author":"Ji","year":"2010","journal-title":"Eur J Haematol"},{"key":"R11-10-20251014","doi-asserted-by":"crossref","first-page":"12191223","DOI":"10.1007\/s00277-011-1241-0","article-title":"Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negativehepatitis B core antibody positive patients receiving rituximabcontaining combination chemotherapy without routine antiviral prophylaxis.","volume":"90","author":"Koo","year":"2011","journal-title":"Ann Hematol"},{"key":"R12-10-20251014","doi-asserted-by":"crossref","first-page":"e2e16","DOI":"10.1016\/j.ijid.2010.03.025","article-title":"Does rituximab increase the incidence of infectious complications? A narrative review.","volume":"15","author":"Kelesidis","year":"2011","journal-title":"Int J Infect Dis"},{"issue":"Suppl 1","key":"R14-10-20251014","first-page":"S33S44","article-title":"Epidemiology of HBV infection in Asian blood donors: emphasis on occult HBV infection and the role of NAT.","volume":"36","author":"Liu","year":"2006","journal-title":"J Clin Virol"},{"key":"R16-10-20251014","first-page":"330339","article-title":"Hepatitis B screening, prophylaxis and reactivation in the era of rituximabbased chemotherapy.","volume":"31","author":"MendezNavarro","year":"2011","journal-title":"Liver Int"},{"key":"R17-10-20251014","doi-asserted-by":"crossref","first-page":"12441253","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for nonHodgkins lymphoma.","volume":"17","author":"Cheson","year":"1999","journal-title":"J Clin Oncol"},{"key":"R18-10-20251014","doi-asserted-by":"crossref","first-page":"659666","DOI":"10.1016\/j.jhep.2004.06.031","article-title":"Quantification and genotyping of hepatitis B virus in a single reaction by realtime PCR and melting curve analysis.","volume":"41","author":"Yeh","year":"2004","journal-title":"J Hepatol"},{"key":"R20-10-20251014","doi-asserted-by":"crossref","first-page":"27652772","DOI":"10.1200\/JCO.2012.48.5938","article-title":"Randomized controlled trial of entecavir prophylaxis for rituximabassociated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B.","volume":"31","author":"Huang","year":"2013","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"R21-10-20251014","doi-asserted-by":"crossref","first-page":"i6i17","DOI":"10.1136\/gutjnl-2012-302056","article-title":"New insight in the pathobiology of hepatitis B virus infection.","volume":"61","author":"Dandri","year":"2012","journal-title":"Gut"},{"key":"R22-10-20251014","doi-asserted-by":"crossref","first-page":"182184","DOI":"10.1136\/gutjnl-2012-302656","article-title":"Quantitative hepatitis B core antibody level may help predict treatment response in chronic hepatitis B patients.","volume":"62","author":"Yuan","year":"2013","journal-title":"Gut"},{"key":"R23-10-20251014","doi-asserted-by":"crossref","first-page":"e39175","DOI":"10.1371\/journal.pone.0039175","article-title":"Genomewide association study confirming association of HLADP with protection against chronic hepatitis B and viral clearance in Japanese and Korean.","volume":"7","author":"Nishida","year":"2012","journal-title":"PLoS One"},{"key":"R24-10-20251014","doi-asserted-by":"crossref","first-page":"8795","DOI":"10.1111\/j.1365-2141.2008.07571.x","article-title":"Relationship between HLADP supertype and survival in childhood acute lymphoblastic leukaemia: evidence for selective loss of immunological control of residual disease?","volume":"145","author":"Taylor","year":"2009","journal-title":"Br J Haematol"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.26718","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-201406000-00010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T15:54:04Z","timestamp":1760457244000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-201406000-00010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.26718","relation":{},"ISSN":["0270-9139"],"issn-type":[{"value":"0270-9139","type":"print"}],"subject":[],"published":{"date-parts":[[2014,6]]}}}